Advances in the Treatment of Systemic Sclerosis.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 61, doi. 10.17925/RMD.2022.1.2.61
- By:
- Publication type:
- Article
Works matching IS 26351420 AND DT 2022 AND VI 1 AND IP 2
Results: 9
1
2
Osteoarthritis: Advances and Emerging Treatments.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 57, doi. 10.17925/RMD.2022.1.2.57
- By:
- Publication type:
- Article
3
The Complement System in Spondyloarthritis: What Do We Know?
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 50, doi. 10.17925/RMD.2022.1.2.50
- By:
- Publication type:
- Article
4
Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 46, doi. 10.17925/RMD.2022.1.2.46
- By:
- Publication type:
- Article
5
Can I Prevent Developing a Rheumatic and Musculoskeletal Disease Through Lifestyle Changes? A Focus on Nutrition.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 44, doi. 10.17925/RMD.2022.1.2.44
- By:
- Publication type:
- Article
6
Immunomodulation with Methotrexate Improves Treatment Response to Pegloticase in Uncontrolled Gout.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 42, doi. 10.17925/RMD.2022.1.2.42
- By:
- Publication type:
- Article
7
Deucravacitinib: An Oral, Selective, Allosteric Tyrosine kinase 2 Inhibitor for Active Systemic Lupus Erythematosus.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 40, doi. 10.17925/RMD.2022.1.2.40
- By:
- Publication type:
- Article
8
SARS-CoV-2 Vaccine Immunogenicity in Patients with Autoimmune Inflammatory Rheumatic Diseases.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 38, doi. 10.17925/rmd.2022.1.2.38
- By:
- Publication type:
- Article
9
Foreword.
- Published in:
- touchREVIEWS in RMD, 2022, v. 1, n. 2, p. 37
- By:
- Publication type:
- Article